The National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada with ongoing and timely medical, scientific and public health advice relating to immunization. The Public Health Agency of Canada acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and is disseminating this document for information purposes. People administering the vaccine should also be aware of the contents of the relevant product monograph(s). Recommendations for use and other information set out herein may differ from that set out in the product monograph(s) of the Canadian manufacturer(s) of the vaccine(s). Manufacturer(s) have sought approval of the vaccine(s) and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. NACI members and liaison members conduct themselves within the context of the Public Health Agency of Canada's Policy on Conflict of Interest, including yearly declaration of potential conflict of interest. An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) † StAtemeNt oN meASleS-mumPS-RubellA-VARICellA VACCINe Une déclaration d'un comité consultatif (DCC) Comité consultatif national de l'immunisation (CCNI) † DéClARAtIoN SuR le VACCIN CoNtRe lA Rougeole, lA Rubéole, leS oReIlloNS et lA VARICelle †La présente déclaration a été rédigée par D r B. Tan et D re S. Ismail et approuvée par le CCNI. †Membres : D re J. Langley (présidente), D re B. Warshawsky (vice-présidente), D re S. Ismail (secrétaire exécutive), D re N. Crowcroft , M me A

Preamble the national advisory Committee on immunization (naCi) provides the public Health agency of Canada (pHaC) with ongoing and timely medical, scientific and public health advice relating to immunization. pHaC acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and is disseminating this document for information purposes. people administering the vaccine should also be aware of the contents of the relevant product monograph(s). recommendations for use and other information set out herein may differ from that set out in the product monograph(s) of the Canadian manufacturer(s) of the vaccine(s). manufacturer(s) have sought approval of the vaccine(s) and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. naCi members and liaison members conduct themselves within the context of pHaC's policy on Conflict of interest, including yearly declaration of potential conflict of interest.

No abstract